O Shaughnessy Asset Management LLC Buys 1,930 Shares of DexCom, Inc. (NASDAQ:DXCM)

O Shaughnessy Asset Management LLC lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 16.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,384 shares of the medical device company’s stock after buying an additional 1,930 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in DexCom were worth $1,041,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in DXCM. Geode Capital Management LLC raised its stake in DexCom by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock worth $664,056,000 after acquiring an additional 214,136 shares during the period. Jennison Associates LLC raised its position in shares of DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after purchasing an additional 710,858 shares during the period. Norges Bank bought a new position in DexCom in the 4th quarter worth $385,367,000. Groupama Asset Managment boosted its holdings in DexCom by 1.1% in the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after buying an additional 31,358 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in DexCom by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company’s stock worth $219,716,000 after buying an additional 91,051 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on DXCM shares. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Morgan Stanley upped their price target on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Finally, Cfra Research upgraded shares of DexCom to a “hold” rating in a report on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average price target of $99.82.

Insider Activity

In other DexCom news, CEO Kevin R. Sayer sold 32,498 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the sale, the chief executive officer now directly owns 372,029 shares of the company’s stock, valued at $26,183,401.02. The trade was a 8.03 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is currently owned by insiders.

DexCom Stock Up 3.0 %

NASDAQ DXCM opened at $61.63 on Tuesday. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $141.99. The firm has a market capitalization of $24.17 billion, a price-to-earnings ratio of 43.10, a PEG ratio of 2.30 and a beta of 1.50. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a fifty day moving average of $79.63 and a two-hundred day moving average of $76.90.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.